Yes.
Peers post Ph 2b success:
- PAR - Ph 2b success awaiting Ph 3 trial approval $711.5m MC;
- OPT - Ph 2b success awaiting Ph 3 trial approval $809.9m MC.
Undervalued bios have typically run in the lead up to the phase 2 results. E.g. Paradigm released their Phase 2b data on the 18th of December 2018, the closing share price before the announcement was $1.29. 3-month prior $0.946-month $0.67; and12 month $0.24. BTW 0.24 was $47.7m MC - just to highlight how undervalued we are here. It ran to $200m prior to release.
As for OPT, that was $200m prior to results also - end markets of OPT and PAR are not dissimilar.
Stating the obvious here but,Dimerix currently sits 6 months before not one, but two phase two readouts right now. Should see a rerate over next few months given we are at 19.5m EV (could be up to 10x higher based on peer analysis) and a massive rerate upon success. Crazy risking when you think diabetic subset of ph2a achieved 35% and this trial just needs 30% improvement.
8's.
- Forums
- ASX - By Stock
- Taylor's Initiation
Yes.Peers post Ph 2b success:- PAR - Ph 2b success awaiting Ph 3...
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.8¢ |
Change
-0.003(0.71%) |
Mkt cap ! $192.3M |
Open | High | Low | Value | Volume |
35.5¢ | 35.8¢ | 34.5¢ | $542.1K | 1.538M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 167310 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 22835 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 167310 | 0.345 |
13 | 484558 | 0.340 |
6 | 182873 | 0.335 |
10 | 345839 | 0.330 |
6 | 88605 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 10000 | 1 |
0.355 | 218000 | 4 |
0.360 | 455000 | 7 |
0.365 | 156284 | 7 |
0.370 | 677379 | 15 |
Last trade - 10.27am 07/05/2024 (20 minute delay) ? |
|
|||||
Last
34.5¢ |
  |
Change
-0.003 ( 0.83 %) |
|||
Open | High | Low | Volume | ||
35.5¢ | 35.5¢ | 34.5¢ | 434509 | ||
Last updated 10.36am 07/05/2024 ? |
Featured News
DXB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online